Centocor Biologic LLC

Centocor Biologic LLC is a pharmaceutical and biotechnology company, operating as a wholly owned subsidiary of Johnson & Johnson. Centocor was founded in May 1979 and initially focused on developing diagnostic assays using monoclonal antibody technology. It later expanded into therapeutic drug development. While the broader Centocor entity was rebranded as Janssen Biotech, Inc. in 2011 as part of Johnson & Johnson's pharmaceutical segment, Centocor Biologic LLC remains a distinct legal entity within the corporate structure, listed as a U.S. subsidiary headquartered in Pennsylvania.

The company develops and markets biologics, particularly monoclonal antibodies, for the treatment of various diseases. Its major product initiatives have included Remicade (infliximab), used for autoimmune conditions such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis, and ReoPro (abciximab) for cardiology. Centocor's portfolio contributes to Johnson & Johnson's biopharmaceutical offerings.

In terms of patent litigation, Centocor Biologic LLC exhibits the posture of an operating company actively asserting its intellectual property. It has one tracked case as a plaintiff and zero as a defendant in our database. This is consistent with its history of engaging in patent enforcement to protect its biologic drugs, often against other pharmaceutical companies concerning issues like biosimilar development.

The sole tracked case involving Centocor Biologic LLC as a plaintiff is Janssen et al. v. Bio-Thera, filed on February 27, 2026, in the U.S. District Court for the District of Delaware. This case, where Centocor Biologic LLC is a co-plaintiff alongside Janssen, indicates a continued strategy of protecting its patented biologics. The District of Delaware is a common venue for patent litigation, including pharmaceutical disputes.